THE WOODLANDS, Texas, Aug. 12, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated formal preclinical development of LX7101, a new drug candidate for glaucoma. LX7101 is a small molecule compound that may have application in treating glaucoma by lowering fluid pressure in the eye through a new mechanism of action. Glaucoma is a disease of the eye which gradually impairs vision and is a leading cause of blindness in the United States. Upon successful completion of preclinical development, Lexicon plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for LX7101.
